Article Data

  • Views 228
  • Dowloads 102

Original Research

Open Access Special Issue

Evolution of Anxiety and Depression in Men during the First Six Months of the COVID-19 Pandemic and Factors Associated with Worsening of Mental Health: Retrospective Longitudinal Study

  • Ana Lear-Claveras1
  • Alejandra Aguilar-Latorre1
  • Bárbara Oliván-Blázquez1,2,3,*,
  • Sabela Couso-Viana4
  • Ana Clavería-Fontán3,4,5,

1Aragonese Primary Care Research Group (GAIAP, B21_20R), Institute for Health Research Aragón (IIS Aragón), 50009 Zaragoza, Spain

2Department of Psychology and Sociology, University of Zaragoza, 50009 Zaragoza, Spain

3Network for Research on Chronicity, Primary Care and Health Promotion (RICAPPS), 08007 Barcelona, Spain

4I-Saúde Group, South Galicia Health Research Institute, 36201 Vigo, Spain

5Vigo Health Area, SERGAS, 36201 Vigo, Spain

DOI: 10.31083/j.jomh1809182 Vol.18,Issue 9,September 2022 pp.1-10

Published: 22 September 2022

*Corresponding Author(s): Bárbara Oliván-Blázquez E-mail: bolivan@unizar.es

Abstract

Background: The Coronavirus disease (COVID-19) pandemic has had a huge impact on the psychological wellbeing of the population, however, few studies have analysed the psychological consequences for the most vulnerable groups, particularly those suffering from depression and anxiety, and specifically in men. The objective of this study is to analyse the changes in a population of men undergoing active treatment for depression or anxiety and factors associated with these changes. Methods: Retrospective, longitudinal and observational study of a population of 28,294 men in northern Spain. The study variables were sociodemographic variables, chronic comorbidities, COVID-19 infection, anxiolytic and antidepressant drug consumption, and use of healthcare resources. These variables were collected from the Primary Health Care electronic records for the two distinct periods (6 months before and 6 months following the end of the lockdown). To compare drug patterns and the use of healthcare resources a paired Student’s T-test was used. To analyse associated factors related to a deterioration of mental disorders, a multivariate logistic regression was performed. Results: In relation to changes in drug patterns, 40% of men saw an increase in at least one Defined Daily Dose (DDD) of their prescribed drugs during the 6 months following lockdown and the number of appointments at health centres and home visits significantly decreased. Factors associated with a deterioration of mental disorders are being under 60 years old, having an income of less than 18,000 euros/year and suffering from more than one comorbidity. Conclusions: The pandemic had a significant impact on men with a previous diagnosis of depression and/or anxiety.


Keywords

depression; anxiety; men; COVID-19 pandemic; anxiolytic; antidepressant; drug consumption; use of healthcare resources


Cite and Share

Ana Lear-Claveras,Alejandra Aguilar-Latorre,Bárbara Oliván-Blázquez,Sabela Couso-Viana,Ana Clavería-Fontán. Evolution of Anxiety and Depression in Men during the First Six Months of the COVID-19 Pandemic and Factors Associated with Worsening of Mental Health: Retrospective Longitudinal Study. Journal of Men's Health. 2022. 18(9);1-10.

References

[1] Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. The Journal of Mental Health Policy and Economics. 2006; 9: 87–98.

[2] Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Medicine. 2013; 10: e1001547.

[3] Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM, Fernán-dez A, Pinto-Meza A, et al. Epidemiology of major depres-sive episode in a southern European country: Results from the ESEMeD-Spain project. Journal of Affective Disorders. 2010; 120: 76–85.

[4] World Health Organization. WHO methods and data sources for global burden of disease estimates. 2017. Available at: http://www.who.int/gho/mortality_burden_disease/en/index.html (Accessed: 11 January 2022).

[5] World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates: internet report. Global Health Estimates: Geneva, Switzerland. 2017.

[6] Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Use of mental health services in Europe: Re-sults from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta psychiatrica Scandinavica. Supplementum. 2004; 109: 47–54.

[7] Roca M, Gili M, Garcia-Garcia M, Salva J, Vives M, Garcia Campayo J, et al. Prevalence and comorbidity of common mental disorders in primary care. Journal of Affective Disorders. 2009; 119: 52–58.

[8] Kennedy N, Abbott R, Paykel ES. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cam-bridge cohort. Psychological Medicine. 2003; 33: 827–838.

[9] Cervilla JA, Rivera M, Molina E, Torres-González F, Bellón JA, Moreno B, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6a4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2006; 141B: 912–917.

[10] Cervilla JA, Molina E, Rivera M, Torres-González F, Bellón JA, Moreno B, et al. The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort. Molecular Psychiatry. 2007; 12: 748–755.

[11] Patten SB, Wang JL, Williams JV, Lavorato DH, Khaled SM, Bulloch AG. Predictors of the Longitudinal Course of Major De-pression in a Canadian Population Sample. The Canadian Journal of Psychiatry. 2010; 55: 669–676.

[12] Bellón JÁÁ, de Dios Luna J, King M, Moreno-Küstner B, Nazareth I, Montón-Franco C, et al. Predicting the onset of ma-jor depression in primary care: international validation of a risk prediction algorithm from Spain. Psychological Medicine. 2011; 41: 2075–2088.

[13] Hidaka BH. Depression as a disease of modernity: Explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140: 205–214.

[14] Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. The Lancet. 2012; 379: 1045–1055.

[15] Probst JC, Laditka SB, Moore CG, Harun N, Powell MP, Baxley EG. Rural-urban differences in depression prevalence: implica-tions for family medicine. Family Medicine. 2006; 38(9):653–60.

[16] Annequin M, Weill A, Thomas F, Chaix B. Environmental and individual characteristics associated with depressive disorders and mental health care use. Annals of Epidemiology. 2015; 25: 605–612.

[17] O’Hare C, O’Sullivan V, Flood S, Kenny RA. Seasonal and meteorological associations with depressive symptoms in older adults: a geo-epidemiological study. Journal of Affective Disor-ders. 2016; 191: 172–179.

[18] Wang JL. Rural-urban differences in the prevalence of major de-pression and associated impairment. Social Psychiatry and Psy-chiatric Epidemiology. 2004; 39: 19–25.

[19] Weich S, Twigg L, Lewis G. Rural/non-rural differences in rates of common mental disorders in Britain: prospective multilevel cohort study. The British Journal of Psychiatry. 2006; 188: 51–57.

[20] Kim SE, Kim HN, Cho J, Kwon MJ, Chang Y, Ryu S, et al. Di-rect and Indirect Effects of Five Factor Personality and Gender on Depressive Symptoms Mediated by Perceived Stress. PLoS ONE. 2016; 11: e0154140.

[21] Vives M, García-Toro M, Armengol S, Perez MC, Fernández JR, Gili M. Prevalence and factors associated to mental disorders in primary care attenders aged 75 and older. Actas Españolas de Psiquiatría. 2013; 41: 218–226.

[22] Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, et al. Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study. Medicina Clínica. 2006; 126: 445–451.

[23] Gili M, Garcia-Toro M, Vives M, Armengol S, Garcia-Campayo J, Soriano JB, et al. Medical comorbidity in recurrent versus first-episode depressive patients. Acta Psychiatrica Scandinav-ica. 2011; 123: 220–227.

[24] Kessler RC, Bromet EJ. The Epidemiology of Depression across Cultures. Annual Review of Public Health. 2013; 34: 119–138.

[25] Salk RH, Hyde JS, Abramson LY. Gender differences in depres-sion in representative national samples: Meta-analyses of diag-noses and symptoms. Psychological Bulletin. 2017; 143: 783–822.

[26] Parker G, Brotchie H. Gender differences in depression. Interna-tional Review of Psychiatry. 2010; 22: 429–436.

[27] Gum AM, King-Kallimanis B, Kohn R. Prevalence of Mood, Anxiety, and Substance-Abuse Disorders for Older Americans in the National Comorbidity Survey-Replication. The American Journal of Geriatric Psychiatry. 2009; 17: 769–781.

[28] Hinz A, Herzberg PY, Lordick F, Weis J, Faller H, Brähler E, et al. Age and gender differences in anxiety and depression in cancer patients compared with the general population. European Journal of Cancer Care. 2019; 28: e13129.

[29] Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the who World Mental Health Survey Initiative. Depression and Anxiety. 2010; 27: 351–364.

[30] Trainor K, Mallett J, Rushe T. Age related differences in mental health scale scores and depression diagnosis: Adult responses to the CIDI-SF and MHI-5. Journal of Affective Disorders. 2013; 151: 639–645.

[31] Quilez Clavero A. Disfruta de la experiencia, retrospectiva de una iniciativa de envejecimiento saludable en Andorra (Teruel), 2003-2016. Acciones e Investigaciones Sociales. 2017; 37: 165–185.

[32] Koster A, Bosma H, Kempen GIJM, Penninx BWJH, Beekman ATF, Deeg DJH, et al. Socioeconomic differences in incident de-pression in older adults: the role of psychosocial factors, physical health status, and behavioral factors. Journal of Psychosomatic Research. 2006; 61: 619–627.

[33] Weich S, Nazareth I, Morgan L, King M. Treatment of depression in primary care. Socio-economic status, clinical need and receipt of treatment. British Journal of Psychiatry. 2007; 191: 164–169.

[34] Bjelland I, Krokstad S, Mykletun A, Dahl AA, Tell GS, Tambs K. Does a higher educational level protect against anxiety and de-pression? The HUNT study. Social Science & Medicine. 2008; 66: 1334–1345.

[35] Lorant V, Croux C, Weich S, Deliège D, Mackenbach J, Ansseau M. Depression and socio-economic risk factors: 7-year longitu-dinal population study. British Journal of Psychiatry. 2007; 190: 293–298.

[36] Plaisier I, Beekman ATF, de Bruijn JGM, de Graaf R, ten Have M, Smit JH, et al. The effect of social roles on mental health: a matter of quantity or quality? Journal of Affective Disorders. 2008; 111: 261–270.

[37] Golden J, Conroy RM, Bruce I, Denihan A, Greene E, Kirby M, et al. Loneliness, social support networks, mood and well-being in community-dwelling elderly. International Journal of Geriatric Psychiatry. 2009; 24: 694–700.

[38] Lino VTS, Portela MC, Camacho LAB, Atie S, Lima MJB. As-sessment of social support and its association to depression, self-perceived health and chronic diseases in elderly individuals re-siding in an area of poverty and social vulnerability in rio de janeiro city, Brazil. LoGerfo J, editor. PLoS ONE. 2013; 8: e71712.

[39] Kim JH, You JW, Song IH. Effects of Socioeconomic Depriva-tion on Depressive Mood: Analysis of the Moderating Effect of Age. Health and Social Welfare Review. 2015; 35: 42–70.

[40] Phelan JC, Link BG, Tehranifar P. Social Conditions as Funda-mental Causes of Health Inequalities: Theory, Evidence, and Policy Implications. Journal of Health and Social Behavior. 2010; 51: S28–S40.

[41] Djernes JK. Prevalence and predictors of depression in popula-tions of elderly: a review. Acta Psychiatrica Scandinavica. 2006; 113: 372–387.

[42] Choi KW, Kim Y, Jeon HJ. Comorbid Anxiety and Depres-sion: Clinical and Conceptual Consideration and Transdiagnos-tic Treatment. Advances in Experimental Medicine and Biology. 2020; 34: 219–235.

[43] Valdés-Florido MJ, López-Díaz Á, Palermo-Zeballos FJ, Martínez-Molina I, Martín-Gil VE, Crespo-Facorro B, et al. Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. Revista De Psiquiatría Y Salud Mental. 2020; 13: 90–94.

[44] Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – a systematic review and meta-analysis. Psychiatry Research. 2020; 291: 113190.

[45] Wu T, Jia X, Shi H, Niu J, Yin X, Xie J, et al. Prevalence of men-tal health problems during the COVID-19 pandemic: a system-atic review and meta-analysis. Journal of Affective Disorders. 2021; 281: 91–98.

[46] Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Ra-soulpoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Globalization and Health. 2020; 16: 57.

[47] Nochaiwong S, Ruengorn C, Awiphan R, Ruanta Y, Boonchieng W, Nanta S, et al. Mental health circumstances among health care workers and general public under the pandemic situation of COVID-19 (HOME-COVID-19). Medicine. 2020; 99: e20751.

[48] Sheridan Rains L, Johnson S, Barnett P, Steare T, Needle JJ, Carr S, et al. Early impacts of the COVID-19 pandemic on mental health care and on people with mental health conditions: frame-work synthesis of international experiences and responses. So-cial Psychiatry and Psychiatric Epidemiology. 2021; 56: 13–24.

[49] Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 Global Pandemic: Implications for People with Schizophrenia and Related Disorders. Schizophrenia Bulletin. 2020; 46: 752–757.

[50] Druss BG. Addressing the COVID-19 Pandemic in Populations with Serious Mental Illness. JAMA Psychiatry. 2020; 77: 891.

[51] Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psy-chiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain, Behavior, and Immunity. 2020; 87: 100–106.

[52] Liu CH, Stevens C, Conrad RC, Hahm HC. Evidence for elevated psychiatric distress, poor sleep, and quality of life concerns dur-ing the COVID-19 pandemic among U.S. young adults with sus-pected and reported psychiatric diagnoses. Psychiatry Research. 2020; 292: 113345.

[53] WHO. Pulse survey on continuity of essential health ser-vices during the COVID-19 pandemic. 2020. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1 (Accessed: 13 February 2020).

[54] Gobierno de Aragón. Padrón Municipal. Población residente en Aragón por provincia de residencia, según sexo y grandes grupos de edad 2020. 2020. Available at: https://www.aragon.es/-/cifras-oficiales-de-poblacion (Accessed: 13 February 2022).

[55] Calderón-Larrañaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfí A, et al. Assessing and Measur-ing Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2017; 72: 1417–1423.

[56] General Council of Official Pharmaceutical Colleges. Bot Plus. Health Knowledge Database. Madrid (Spain) 2018. Available at: https://botplusweb.portalfarma.com// (Accessed: 13 Febru-ary 2022).

[57] Spanish Society of Family and Community Medicine [semFYC]. Therapeutic Guide in Primary Care‚ Based on the Reasonable Se-lection of Medications. Madrid (Spain). 2019. Available at: https://guiaterapeutica.net/problemas_libres/ (Accessed: 13 Febru-ary 2022).

[58] Lubin Pigouche P, Maciá Antón MA R de LP. Mathematical psy-chology. Madrid: Universidad Nacional de Educación a Distan-cia. 2005.

[59] IBM Corp. SPSS statistic for Windows. Version 25.0. IBM Corp., Armonk, N.Y., USA. 2017. Available at: https://www.ibm.com/es-es/analytics/spss-statistics-software (Accessed: 15 January 2022).

[60] R Core Team. R: A language and environment for statistical com-puting. R Foundation for Statistical Computing, Vienna, Aus-tria. 2019. Available at: https://www.r-project.org/ (Accessed: 15 January 2022).

[61] Llorente JM, Oliván-Blázquez B, Zuñiga-Antón M, Masluk B, Andrés E, García-Campayo J, et al. Variability of the Preva-lence of Depression in Function of Sociodemographic and Envi-ronmental Factors: Ecological Model. Frontiers in Psychology. 2018; 9: 2182.

[62] Keers R, Aitchison KJ. Gender differences in antidepressant drug response. International Review of Psychiatry. 2010; 22: 485–500.

[63] Grigoriadis S, Robinson GE. Gender issues in depression. An-nals of Clinical Psychiatry. 2007; 19: 247–255.

[64] Cassano P, Fava M. Depression and public health: An overview. Journal of Psychosomatic Research. 2002; 53: 849–857.

[65] O’Neil A, Jacka FN, Quirk SE, Cocker F, Taylor CB, Oldenburg B, et al. A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control. BMC Psychiatry. 2015; 15: 15.

[66] Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical ill-ness. Biological Psychiatry. 2003; 54: 216–226.

[67] Aragonès E, Piñol JL, Labad A, Masdéu RM, Pino M, Cervera J. Prevalence and Determinants of Depressive Disorders in Primary Care Practice in Spain. The International Journal of Psychiatry in Medicine. 2004; 34: 21–35.

[68] Taquet M, Holmes EA, Harrison PJ. Depression and anxiety dis-orders during the COVID-19 pandemic: knowns and unknowns. The Lancet. 2021; 398: 1665–1666.

[69] Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ash-baugh C, Pigott DM, et al. Global prevalence and burden of de-pressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. 2021; 398: 1700–1712.

[70] Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain, Behavior, and Immunity. 2020; 89: 531–542.

[71] Moitra M, Santomauro D, Degenhardt L, Collins PY, Whiteford H, Vos T, et al. Estimating the risk of suicide associated with

mental disorders: a systematic review and meta-regression anal-ysis. Journal of Psychiatric Research. 2021; 137: 242–249.

[72] Spanish Foundation for the prevention of suicide. Suicide Obser-vatory in Spain. 2021. Available at: /www.fsme.es/observatorio-del-suicidio-2020/ (Accessed: 2 February 2022).

[73] Serna MC, Cruz I, Real J, Gascó E, Galván L. Duration and ad-herence of antidepressant treatment (2003 to 2007) based on pre-scription database. European Psychiatry. 2010; 25: 206–213.

[74] National Clinical Practice Guideline. Depression: Treatment and management of depression in adults. NICE Guideline: London, United Kingdom. 2009.

[75] Álvarez M, Atienza Merino G, José GÁM, González García A, Guitián Rodríguez D, De las Heras Liñero E, et al. Guía de Prác-tica Clínica sobre el manejo de la depresión en el adulto. Minist Sanidad, Serv Soc e Igualdad Agencia Evaluación Tecnol Sanit Galicia. 2014; 61: 38–41. (In Spanish)

[76] Martinelli N, Gil S, Chevalère J, Belletier C, Dezecache G, Huguet P, et al. The Impact of the COVID-19 Pandemic on Vulnerable People Suffering from Depression: Two Studies on Adults in France. International Journal of Environmental Re-search and Public Health. 2021; 18: 1–12.

[77] Chatterjee SS, Barikar C M, Mukherjee A. Impact of COVID-19 pandemic on pre-existing mental health problems. Asian Journal of Psychiatry. 2020; 51: 102071.

[78] World Health Organization. The impact of COVID-19 on mental, neurological and substance use services. 2020. Available at: https://www.who.int/publications/i/item/978924012455 (Accessed: 17 February 2020).

[79] García-Álvarez L, de la Fuente-Tomás L, García-Portilla MP, Sáiz PA, Lacasa CM, Santo FD, et al. Early psychological im-pact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample. Journal of Global Health. 2020; 10: 1–15.

[80] Whooley MA, Kiefe CI, Chesney MA, Markovitz JH, Matthews K, Hulley SB. Depressive Symptoms, Unemployment, and Loss of Income. Archives of Internal Medicine. 2002; 162: 2614.

[81] Beutel ME, Glaesmer H, Wiltink J, Marian H, Brähler E. Life sat-isfaction, anxiety, depression and resilience across the life span of men. The Aging Male. 2010; 13: 32–39.

[82] Van Hal G. The true cost of the economic crisis on psychological well-being: a review. Psychology Research and Behavior Man-agement. 2015; 8: 17.

[83] Gili M, Roca M, Basu S, McKee M, Stuckler D. The mental health risks of economic crisis in Spain: evidence from primary care centres, 2006 and 2010. European Journal of Public Health. 2013; 23: 103–108.

[84] Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin-ical Psychology Review. 2007; 27: 959–985.

[85] Ostler K, Thompson C, Kinmonth A-K, Peveler RC, Stevens L, Stevens A. Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care. British Journal of Psychiatry. 2001; 178: 12–17.

[86] Hägg S, Jylhävä J, Wang Y, Xu H, Metzner C, Annetorp M, et al. Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients with Coronavirus Disease 2019 in Geriatric Care. Journal of the American Medical Directors As-sociation. 2020; 21: 1555–1559.e2.

[87] Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID‐19 patients: a systematic review and meta‐analysis. Journal of Medical Virol-ogy. 2020; 92: 1875–1883.

[88] Li Y, Ashcroft T, Chung A, Dighero I, Dozier M, Horne M, et al. Risk factors for poor outcomes in hospitalised COVID-19 pa-tients: A systematic review and meta-analysis. Journal of Global Health. 2021; 11: 10001.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus CiteScore 0.7 (2021) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top